Literature DB >> 23442237

Current devices for pediatric extracorporeal life support and mechanical circulatory support systems in the United States.

Akif Undar1, Shigang Wang.   

Abstract

Extracorporeal life support (ECLS) and mechanical circulatory support (MCS) have become indispensable treatment tools for pediatric patients with congenital heart defects undergoing peri-operative or end-stage heart and/or lung failure. ECLS and MCS can serve as bridges to recovery, transplantation (heart or lung), destination therapy, or "bridge to bridge" long-term MCS. Dependent on patient condition, venoarterial ECMO (V-A ECMO) for heart and lung support, venovenous ECMO (V-V ECMO) for respiratory support, and MCS for uni- and biventricular support can be selected properly. Considering small patient body size, the access sites and cannulation should be selected carefully to obtain adequate blood flow, minimum injury, and easy management. The applying equipment, including tubing, cannulae, oxygenator and blood pump, need to be selected optimally in order to enable rapid setup and priming, successful cannulation and early support, and to reduce the risk of device-related morbidity and mortality. The aim of this review manuscript was to discuss briefly the current devices for pediatric ECLS and MCS available in US.

Entities:  

Mesh:

Year:  2013        PMID: 23442237     DOI: 10.3233/BME-120732

Source DB:  PubMed          Journal:  Biomed Mater Eng        ISSN: 0959-2989            Impact factor:   1.300


  2 in total

1.  Triiodothyronine activates lactate oxidation without impairing fatty acid oxidation and improves weaning from extracorporeal membrane oxygenation.

Authors:  Masaki Kajimoto; Dolena R Ledee; Chun Xu; Hidemi Kajimoto; Nancy G Isern; Michael A Portman
Journal:  Circ J       Date:  2014-10-28       Impact factor: 2.993

2.  Successful extracorporeal membrane oxygenation (ECMO) support in two pediatric heart transplant patients with extreme donor/recipient size mismatch.

Authors:  Ping Li; Nianguo Dong; Yang Zhao; Sihai Gao
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.